These findings are herein reviewed and shed light onto their relevance for the future development of novel agonists and antagonists of the TLR4/MD-2 system with promising biomedical applications in sepsis, inflammation, vaccines and cancer immunotherapy, among others. This evidence concerns the gene LY96 and cancer.